Peripheral blood CD26 positive leukemic stem cells as a possible diagnostic and prognostic marker in chronic myeloid leukemia

Riether, 2015, Regulation of hematopoietic and leukemic stem cells by the immune system, Cell Death Differ., 22, 187, 10.1038/cdd.2014.89 Herrmann, 2014, Dipeptidylpeptidase IV (CD26) defines leukemic stem cells (LSC) in chronic myeloid leukemia, Blood, 123, 3951, 10.1182/blood-2013-10-536078 Susanne, 2018, Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EUROSKI): a prespecified interim analysis of a prospective multicentre, non-randomised, trial, Lancet Oncol., 19, 747, 10.1016/S1470-2045(18)30192-X María S.R., BelénM, Bonecker S, Furtado C., Koile D. miRNome profiling of clonal stem cells in Ph+ CML bioRxiv preprint. doi: 10.1101/2020.03.16.989194. This version posted March 18, 2020. Rea, 2017, Discontinuation of dasatinib or nilotinib in chronic myeloid leukemia: interim analysis of the STOP 2G-TKI study, Blood, 129, 846, 10.1182/blood-2016-09-742205 Hughes, 2016, Moving treatment-free remission into mainstreamclinical practice in CML, Blood, 128, 17, 10.1182/blood-2016-01-694265 Hamilton, 2012, Chronic myeloid leukemia stem cells are not dependent on Bcr-Ablkinase activity for their survival, Blood, 119, 1501, 10.1182/blood-2010-12-326843 Cheloni, 2017, The leukemic stem cell niche: adaptation to “Hypoxia” versus oncogene addiction, Stem Cells Int., 4979474 Jiang, 2014, Distinguishing CML LSCs from HSCs using CD26, Blood, 123, 3851, 10.1182/blood-2014-05-574293 Valent, 2014, DPPIV (CD26) as a novel stem cell marker in Ph+ chronic myeloid leukemia, Eur. J. Clin. Investig., 44, 1239, 10.1111/eci.12368 Culen, 2016, Quantitative assessment of the CD26+ leukemic stem cell compartment in chronic myeloid leukemia: patient-subgroups, prognostic impact, and technical aspects, Oncotarget, 7, 33016, 10.18632/oncotarget.9108 Cumbo, 2020, Monitoring of minimal residual disease (MRD) in chronic myeloid leukemia: recent advances, Cancer Manag. Res., 12, 3175, 10.2147/CMAR.S232752 Warfving, 2017, Single-cell molecular analysis defines therapy response and immunophenotype of stem cell subpopulations in CML, Blood, 129, 2384, 10.1182/blood-2016-07-728873 Raspadori, 2019, Flow cytometry assessment of CD26+ leukemic stem cells in peripheral blood: a simple and rapid new diagnostic tool for chronic myeloid leukemia, Cytom. B Clin. Cytom., 96B, 294, 10.1002/cyto.b.21764 Bocchia, 2018, Residual peripheral blood CD26 + leukemic stem cells in chronic myeloid leukemia patients during TKI therapy and during treatment-free remission, Front. Oncol., 8, 194, 10.3389/fonc.2018.00194 Orrù, 2013, Genetic variant sregulating immune cell levels in health and disease, Cell, 155, 242, 10.1016/j.cell.2013.08.041 Baccarani, 2013, European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013, Blood, 122, 872, 10.1182/blood-2013-05-501569 Machado, 2011, Monitoring of BCR-ABL levels in chronic myeloid leukemia patients treated with imatinib in the chronic phase - the importance of a major molecular response, Rev. Bras. Hematol. Hemoter., 33, 211, 10.5581/1516-8484.20110056 Branford, 2006, Rationale for the recommendations for harmonizing current methodology for detecting BCR-ABL transcripts In patients with chronic myeloid leukaemia, Leukemia, 20, 1925, 10.1038/sj.leu.2404388 Minciacchi, 2021, Chronic myeloid leukemia: a model disease of the past, present and future, Cells, 10, 117, 10.3390/cells10010117 GalimbertiS, 2018, The polycomb BMI1 protein isco-expressed with CD26+ in leukemic stem cells of chronic myeloidleukemia, Front. Oncol., 8 Ashariati, 2013, Prognostic score in chronic myeloid leukemia patients treated with Imatinib, Acta Med. Indones., 45, 107 Ross, 2018, Long-term treatment-free remission of chronic myeloid leukemia with falling levels of residual leukemic cells, Leukemia, 32, 2572, 10.1038/s41375-018-0264-0 Annunziata, 2020, Current strategies and future molecular response and directions to achieve deep molecular response and treatment-free remission in chronic myeloid leukemia, Front. Oncol., 10, 883, 10.3389/fonc.2020.00883 Hochhaus, 2020, European leukemia net 2020 recommendations for treating chronic myeloid leukemia, Leukemia, 34, 966, 10.1038/s41375-020-0776-2 Hehlmann, 2020, Chronic myeloid leukemia in 2020, Hemasphere, 4, e468, 10.1097/HS9.0000000000000468 Ilhan, 2021, Leukemic stem cells shall be searched in the bone marrow before “tyrosine kinase inhibitor-discontinuation” in chronic myeloid leukemia, Int. J. Lab. Hematol., 43, 1110, 10.1111/ijlh.13528